1. A tutorial on time-dependent cohort state-transition models in R using a cost-effectiveness analysis example
    Fernando Alarid-Escudero, Eline Krijkamp, Eva A Enns, Alan Yang, MG Myriam Hunink, Petros Pechlivanoglou, and Hawre Jalal
    Medical Decision Making, 2023
  2. An introductory tutorial on cohort state-transition models in R using a cost-effectiveness analysis example
    Fernando Alarid-Escudero, Eline Krijkamp, Eva A Enns, Alan Yang, MG Myriam Hunink, Petros Pechlivanoglou, and Hawre Jalal
    Medical Decision Making, 2023
  3. Approaches to developing de novo cancer population models to examine questions about cancer and race in bladder, gastric, and endometrial cancer and multiple myeloma: the Cancer Intervention and Surveillance Modeling Network incubator program
    Yuliia Sereda, Fernando Alarid-Escudero, Nina A Bickell, Su-Hsin Chang, Graham A Colditz, Chin Hur, Hawre Jalal, Evan R Myers, Tracy M Layne, Shi-Yi Wang, and  others
    JNCI Monographs, 2023


  1. Exponential growth of drug overdose poisoning and opportunities for intervention
    Hawre Jalal, and Donald S Burke
    Addiction, 2022
  2. Reply commentary by Jalal and Burke.
    Donald S Burke, and Hawre Jalal
    The International Journal on Drug Policy, 2022
  3. APCtools: Descriptive and Model-based Age-Period-Cohort Analysis
    Alexander Bauer, Maximilian Weigert, and Hawre Jalal
    Journal of Open Source Software, 2022


  1. baycann.png
    BayCANN: streamlining Bayesian calibration with artificial neural network metamodeling
    Hawre Jalal, Thomas A Trikalinos, and Fernando Alarid-Escudero
    Frontiers in Physiology, 2021
  2. Carfentanil and the rise and fall of overdose deaths in the United States
    Hawre Jalal, and Donald S Burke
    Addiction, 2021
  3. Microsimulation model to compare enteral and parenteral iron supplementation in children with intestinal failure
    Vikram Kalathur Raghu, Jeffrey A Rudolph, Hawre J Jalal, and Kenneth J Smith
    Journal of Parenteral and Enteral Nutrition, 2021
  4. Future projection of the health and functional status of older people in Japan: A multistate transition microsimulation model with repeated cross-sectional data
    Megumi Kasajima, Hideki Hashimoto, Sze-Chuan Suen, Brian Chen, Hawre Jalal, Karen Eggleston, and Jay Bhattacharya
    Health Economics, 2021
  5. Data needs in opioid systems modeling: challenges and future directions
    Mohammad S Jalali, Emily Ewing, Calvin B Bannister, Lukas Glos, Sara Eggers, Tse Yang Lim, Erin Stringfellow, Celia A Stafford, Rosalie Liccardo Pacula, Hawre Jalal, and  others
    American journal of preventive medicine, 2021
  6. Towards a Public Health Approach to Homicides in Mexico
    Andrea Luviano, Hawre Jalal, Alfonso Miranda, Alejandro Madrazo, Michael Reich, and Fernando Alarid-Escudero
    Available at SSRN 3795313, 2021
  7. Is further research on adult pneumococcal vaccine uptake improvement programs worthwhile? A value of information analysis
    Angela R Wateska, Mary Patricia Nowalk, Hawre Jalal, Chyongchiou J Lin, Lee H Harrison, William Schaffner, Richard K Zimmerman, and Kenneth J Smith
    Vaccine, 2021
  8. How simulation modeling can support the public health response to the opioid crisis in North America: setting priorities and assessing value
    Nicholas J Bansback, Carolina Barbosa, Joshua Barocas, Ahmed M Bayoumi, Czarina Behrends, Jag Chhatwal, Lauren E Cipriano, Phillip Coffin, Jeremy Goldhaber-Fiebert, Jeffrey S Hoch, and  others
    International Journal of Drug Policy, 2021
  9. Prominent spatiotemporal waves of COVID-19 incidence in the United States: Implications for causality, forecasting, and control
    Hawre Jalal, Kyueun Lee, and Donald S Burke
    medRxiv, 2021
  10. Recurring Spatiotemporal Patterns of COVID-19 in the United States
    Hawre Jalal, Kyueun Lee, and Donald S Burke
    medRxiv, 2021


  1. nature_med.png
    Age and generational patterns of overdose death risk from opioids and other drugs
    Hawre Jalal, Jeanine M Buchanich, David R Sinclair, Mark S Roberts, and Donald S Burke
    Nature medicine, 2020
  2. Calculating the expected value of sample information in practice: considerations from 3 case studies
    Anna Heath, Natalia Kunst, Christopher Jackson, Mark Strong, Fernando Alarid-Escudero, Jeremy D Goldhaber-Fiebert, Gianluca Baio, Nicolas A Menzies, and Hawre Jalal
    Medical Decision Making, 2020
  3. A multidimensional array representation of state-transition model dynamics
    Eline M Krijkamp, Fernando Alarid-Escudero, Eva A Enns, Petros Pechlivanoglou, MG Myriam Hunink, Alan Yang, and Hawre J Jalal
    Medical Decision Making, 2020
  4. Associations between the specialty of opioid prescribers and opioid addiction, misuse, and overdose outcomes
    Carroline P Lobo, Gerald Cochran, Chung-Chou H Chang, Walid F Gellad, Adam J Gordon, Hawre Jalal, Wei-Hsuan Lo-Ciganic, Jordan F Karp, David Kelley, and Julie M Donohue
    Pain Medicine, 2020
  5. Computing PROPr utility scores for PROMIS\textregistered profile instruments
    Barry Dewitt, Hawre Jalal, and Janel Hanmer
    Value in Health, 2020
  6. Computing the expected value of sample information efficiently: practical guidance and recommendations for four model-based methods
    Natalia Kunst, Edward CF Wilson, David Glynn, Fernando Alarid-Escudero, Gianluca Baio, Alan Brennan, Michael Fairley, Jeremy D Goldhaber-Fiebert, Chris Jackson, Hawre Jalal, and  others
    Value in Health, 2020
  7. Developing and validating metamodels of a microsimulation model of infant HIV testing and screening strategies used in a decision support tool for health policy makers
    Djøra I Soeteman, Stephen C Resch, Hawre Jalal, Caitlin M Dugdale, Martina Penazzato, Milton C Weinstein, Andrew Phillips, Taige Hou, Elaine J Abrams, Lorna Dunning, and  others
    MDM Policy & Practice, 2020
  8. Dissemination science to advance the use of simulation modeling: our obligation moving forward
    Bohdan Nosyk, Janet Weiner, Emanuel Krebs, Xiao Zang, Benjamin Enns, Czarina N Behrends, Daniel J Feaster, Hawre Jalal, Brandon DL Marshall, Ankur Pandya, and  others
    Medical Decision Making, 2020
  9. Hexamaps for age-period-cohort data visualization and implementation in R
    Hawre Jalal, and Donald S Burke
    Epidemiology (Cambridge, Mass.), 2020
  10. Prioritizing additional data collection to reduce decision uncertainty in the HIV/AIDS response in 6 US cities: a value of information analysis
    Xiao Zang, Hawre Jalal, Emanuel Krebs, Ankur Pandya, Haoxuan Zhou, Benjamin Enns, and Bohdan Nosyk
    Value in Health, 2020


  1. The curve of optimal sample size (COSS): a graphical representation of the optimal sample size from a value of information analysis
    Eric Jutkowitz, Fernando Alarid-Escudero, Karen M Kuntz, and Hawre Jalal
    Pharmacoeconomics, 2019
  2. “Time traveling is just too dangerous” but some methods are worth revisiting: the advantages of expected loss curves over cost-effectiveness acceptability curves and frontier
    Fernando Alarid-Escudero, Eva A Enns, Karen M Kuntz, Tzeyu L Michaud, and Hawre Jalal
    Value in Health, 2019
  3. A need for change! A coding framework for improving transparency in decision modeling
    Fernando Alarid-Escudero, Eline M Krijkamp, Petros Pechlivanoglou, Hawre Jalal, Szu-Yu Zoe Kao, Alan Yang, and Eva A Enns
    Pharmacoeconomics, 2019


  1. 361_aau1184_fa.jpeg
    Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016
    Hawre Jalal, Jeanine M Buchanich, Mark S Roberts, Lauren C Balmert, Kun Zhang, and Donald S Burke
    Science, 2018
  2. GA.png
    A Gaussian approximation approach for value of information analysis
    Hawre Jalal, and Fernando Alarid-Escudero
    Medical Decision Making, 2018
  3. Microsimulation modeling for health decision sciences using R: a tutorial
    Eline M Krijkamp, Fernando Alarid-Escudero, Eva A Enns, Hawre J Jalal, MG Myriam Hunink, and Petros Pechlivanoglou
    Medical Decision Making, 2018


  1. An overview of R in health decision sciences
    Hawre Jalal, Petros Pechlivanoglou, Eline Krijkamp, Fernando Alarid-Escudero, Eva Enns, and MG Myriam Hunink
    Medical decision making, 2017
  2. Prioritizing future research on allopurinol and febuxostat for the management of gout: value of information analysis
    Eric Jutkowitz, Fernando Alarid-Escudero, Hyon K Choi, Karen M Kuntz, and Hawre Jalal
    Pharmacoeconomics, 2017
  3. Opportunity Cost Of Non-Rigorous Or Non-Transferable Research: Implications For Cost-Effectiveness Analysis
    F Alarid-Escudero, H Jalal, and TA Trikalinos
    Value in Health, 2017


  1. rheumatoid.png
    Cost-effectiveness of triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis
    Hawre Jalal, James R O’Dell, S Louis Bridges Jr, Stacey Cofield, Jeffrey R Curtis, Ted R Mikuls, Larry W Moreland, and Kaleb Michaud
    Arthritis care & research, 2016
  2. Some health states are better than others: using health state rank order to improve probabilistic analyses
    Jeremy D Goldhaber-Fiebert, and Hawre J Jalal
    Medical Decision Making, 2016
  3. Forecasting trends in disability in a super-aging society: adapting the future elderly model to Japan
    Brian K Chen, Hawre Jalal, Hideki Hashimoto, Sze-chuan Suen, Karen Eggleston, Michael Hurley, Lena Schoemaker, and Jay Bhattacharya
    The Journal of the Economics of Ageing, 2016


  1. Computing expected value of partial sample information from probabilistic sensitivity analysis using linear regression metamodeling
    Hawre Jalal, Jeremy D Goldhaber-Fiebert, and Karen M Kuntz
    Medical Decision Making, 2015
  2. Cost-effectiveness of a statewide campaign to promote aspirin use for primary prevention of cardiovascular disease
    Tzeyu L Michaud, Jean Abraham, Hawre Jalal, Russell V Luepker, Sue Duval, and Alan T Hirsch
    Journal of the American Heart Association, 2015
  3. Automating identification of multiple chronic conditions in clinical practice guidelines
    Tiffany I Leung, Hawre Jalal, Donna M Zulman, Michel Dumontier, Douglas K Owens, Mark A Musen, and Mary K Goldstein
    AMIA Summits on Translational Science Proceedings, 2015


  1. metamodel.png
    Linear regression metamodeling as a tool to summarize and present simulation model results
    Hawre Jalal, Bryan Dowd, François Sainfort, and Karen M Kuntz
    Medical Decision Making, 2013


  1. Network meta-analysis of margin threshold for women with ductal carcinoma in situ
    Shi-Yi Wang, Haitao Chu, Tatyana Shamliyan, Hawre Jalal, Karen M Kuntz, Robert L Kane, and Beth A Virnig
    Journal of the National Cancer Institute, 2012


  1. Including indirect medical care costs from survivor years of life in economic evaluations
    John A Nyman, and Hawre J Jalal
    Pharmacoeconomics, 2011